AMGEN Inc
NASDAQ: AMGN
$321.64
+$2.35 (+0.7%)
Real Time Data Delayed 15 Min.
AMGN Articles
The FDA has approved Allergan's treatment for migraines in adults. The drug is the first of its class to obtain FDA approval, but the new drug will compete with other recently released treatments for...
Published:
Goldman Sachs believes that several health care companies can win, and it has three top picks for 2020 that may seem counterintuitive.
Published:
Monday's top analyst upgrades, downgrades and initiations included Adobe, Amgen, Bank of America, Broadcom, CME, Goldman Sachs, Micron Technology, PepsiCo, UnitedHealth, Urban Outfitters and Vertex...
Published:
The November 29 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Published:
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The November 15 short interest data has been compared with the previous report, and short interest in...
Published:
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The October 31 short interest data has been compared with the previous report, and short interest in...
Published:
Tuesday's top analyst upgrades, downgrades and initiations included Albermarle, Amgen, Applied Materials, Biogen, CRISPR Therapeutics, CrowdStrike, CSX, Kroger, Slack, Teva Pharmaceutical and Xerox.
Published:
Tuesday's top analyst upgrades, downgrades and initiations included Amgen, Beyond Meat, Cisco, Home Depot, Microsoft, RingCentral, Shake Shack, Tilray, Uber, Under Armour and U.S. Steel.
Published:
Last Updated:
When Amgen released its third-quarter financial results after the markets closed on Tuesday, the firm said that it had $3.66 in earnings per share (EPS) and $5.7 billion in revenue. That compared...
Published:
Last Updated:
Amgen is set to report its most recent quarterly results after the closing bell on Tuesday. Wall Street expectations are muted.
Published:
Last Updated:
24/7 Wall St. has put together a preview of AT&T, Facebook, T-Mobile and the other most prominent earnings reports due this week.
Published:
Last Updated:
The October 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Published:
Last Updated:
Credit Suisse and Merrill Lynch made calls in the biotech and pharmaceutical space last week, ahead of coming earnings reports.
Published:
Last Updated:
Friday's top analyst upgrades, downgrades and initiations included Agilent Technologies, Alphabet, Altria, Amazon.com, Boeing, Caterpillar, Chipotle Mexican Grill, E*Trade, Gap, Snap and Twitter.
Published:
Last Updated:
Thursday's top analyst upgrades, downgrades and initiations included Abbott Laboratories, CSX, IBM, Netflix, Occidental Petroleum, Whiting Petroleum, Amgen, Gilead Sciences, Merck and Pfizer.
Published:
Last Updated: